We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK biotechs Destiny Pharma and SporeGen have entered into a collaborative agreement to develop a new preventative treatment for COVID-19, with support from an £800,000 grant from Innovate UK.